» Articles » PMID: 10579978

Hepatocanalicular Bile Salt Export Pump Deficiency in Patients with Progressive Familial Intrahepatic Cholestasis

Overview
Specialty Gastroenterology
Date 1999 Dec 2
PMID 10579978
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Progressive familial intrahepatic cholestasis (PFIC), an inherited liver disease of childhood, is characterized by cholestasis and either normal or increased serum gamma-glutamyltransferase activity. Patients with normal gamma-glutamyltransferase activity have mutations of the FIC1 locus on chromosome 18q21 or mutations of the BSEP gene on chromosome 2q24. Also, patients with bile acid synthesis defects have low gamma-glutamyltransferase activity. We investigated expression of the bile salt export pump (BSEP) in liver samples from patients with a PFIC phenotype and correlated this with BSEP gene mutations.

Methods: BSEP and multidrug resistance protein 2 (MRP2) expressions were studied by immunohistochemistry in liver specimens of 28 patients and BSEP gene mutation analysis in 19 patients. Bile salt kinetics were studied in 1 patient.

Results: Sixteen of 28 liver samples showed no canalicular BSEP staining. Staining for MRP2 showed a normal canalicular pattern in all but 1 of these samples. Ten of 19 patients showed BSEP gene mutations; BSEP protein expression was lacking in all 10 patients. No mutations were found in 9 of 19 patients, and in all except 1, BSEP protein expression was normal. Bile salt concentration in bile of BSEP-negative/MRP2-positive PFIC patients was 0.2 +/- 0.2 mmol/L (n = 9; <1% of normal) and in BSEP-positive PFIC patients 18.1 +/- 9.9 mmol/L (n = 3; 40% of normal). The kinetic study confirmed the dramatic decrease of bile salt secretion in BSEP-negative patients.

Conclusions: The findings show a close correlation between BSEP gene mutations and canalicular BSEP expression. Biliary secretion of bile salts is greatly reduced in BSEP-negative patients.

Citing Articles

In Vitro-In Silico Models to Elucidate Mechanisms of Bile Acid Disposition and Cellular Aerobics in Human Hepatocytes.

De Vos K, Mols R, Chatterjee S, Huang M, Augustijns P, Wolters J AAPS J. 2025; 27(2):51.

PMID: 40016501 DOI: 10.1208/s12248-024-01010-9.


Efficacy and Safety of Ileal Bile Acid Transport Inhibitors in Inherited Cholestatic Liver Disorders: A Meta-analysis of Randomized Controlled Trials.

Imran M, Elsnhory A, Ibrahim A, Elnaggar M, Tariq M, Mehmood A J Clin Exp Hepatol. 2025; 15(3):102462.

PMID: 39802553 PMC: 11720443. DOI: 10.1016/j.jceh.2024.102462.


Interleukin 1 β suppresses bile acid-induced BSEP expression via a CXCR2-dependent feedback mechanism.

Angendohr C, Missing L, Ehlting C, Wolf S, Lang K, Vucur M PLoS One. 2024; 19(12):e0315243.

PMID: 39680527 PMC: 11649129. DOI: 10.1371/journal.pone.0315243.


The spectrum of novel ABCB11 gene variations in children with progressive familial intrahepatic cholestasis type 2 in Pakistani cohorts.

Riaz H, Zheng B, Zheng Y, Liu Z, Gu H, Imran M Sci Rep. 2024; 14(1):18876.

PMID: 39143102 PMC: 11324741. DOI: 10.1038/s41598-024-59945-0.


Dual Deletion of and Genes in Liver Leads to Hepatomegaly and Hypercholesterolemia.

Wakabayashi N, Yagishita Y, Joshi T, Kensler T Int J Mol Sci. 2024; 25(9).

PMID: 38731931 PMC: 11083431. DOI: 10.3390/ijms25094712.